Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase III Pipeline Programs

Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Programs 5,427
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 5,427 phase iii pharmaceutical pipeline programs from ClinicalTrials.gov. Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Top sponsors

Pipeline programs

Page 10 of 114

  1. APHP191047

    Pari Pharma GmbH

    Patients with microcirculatory abnormalities during septic shock

    phase 3 small molecule active

    1 trial

  2. APHP191099

    Pari Pharma GmbH

    Patients hospitalised in intensive care, diagnosed with sepsis less than 48 hours ago, uric acid level ≥200µmol/L, adults, negative G6PD deficiency

    phase 3 small molecule active

    1 trial

  3. APHP191105

    Pari Pharma GmbH

    Sarcoidosis

    phase 3 small molecule active

    1 trial

  4. APHP191110

    Pari Pharma GmbH

    Patients admitted to the ICU proven or suspected infection as the main diagnosis.

    phase 3 small molecule active

    1 trial

  5. APHP200009

    Pari Pharma GmbH

    Kawasaki disease

    phase 3 small molecule active

    1 trial

  6. APHP200011

    Pari Pharma GmbH

    Intensive care, Ventilator Associated Pneumonia

    phase 3 small molecule active

    1 trial

  7. APHP200017

    Pari Pharma GmbH

    Adult patients with immune thrombocytopenia (ITP) with mild to severe bleeding manifestations

    phase 3 small molecule active

    1 trial

  8. APHP200018

    Pari Pharma GmbH

    Critically ill patients suffering from CIRCI

    phase 3 small molecule active

    1 trial

  9. APHP200019

    Pari Pharma GmbH

    Patient with sepsis complicated by ARDS

    phase 3 small molecule active

    1 trial

  10. APHP200026

    Pari Pharma GmbH

    Patients with GPA and inadequate response to standard of care therapy defined as an inadequate response to either a combination of glucocorticoids plus cyclophosphamide AND/OR a combination of glucocorticoids plus rituximab.

    phase 3 small molecule active

    1 trial

  11. APHP200031

    Pari Pharma GmbH

    Adult women with recurrent implantation failures (RIF)

    phase 3 small molecule active

    1 trial

  12. APHP200038

    Pari Pharma GmbH

    lupus nephritis

    phase 3 small molecule active

    1 trial

  13. APHP200043

    Pari Pharma GmbH

    Hemoptysis, whatever the cause, with the exception of cystic fibrosis

    phase 3 small molecule active

    1 trial

  14. APHP200046

    Pari Pharma GmbH

    HPV vaccine

    phase 3 small molecule active

    1 trial

  15. APHP200056

    Pari Pharma GmbH

    Remyelination in Multiple Sclerosis

    phase 3 other active

    1 trial

  16. APHP200068

    Pari Pharma GmbH

    Adult ICU patients with septic shock

    phase 3 small molecule active

    1 trial

  17. APHP200072

    Pari Pharma GmbH

    Patients referred for an isolated or a combined surgical correction of functional moderate to severe tricuspid regurgitation

    phase 3 small molecule active

    1 trial

  18. APHP200073

    Pari Pharma GmbH

    Erythema multiforme (EM) in its severe form managed at the hospital

    phase 3 small molecule active

    1 trial

  19. APHP201098

    Pari Pharma GmbH

    Adult patients with persistent or chronic immune thrombocytopenia

    phase 3 small molecule active

    1 trial

  20. APHP210089

    Pari Pharma GmbH

    Patients hospitalized for allogeneic hematopoietic stem cell transplantation

    phase 3 small molecule active

    1 trial

  21. APHP210090

    Pari Pharma GmbH

    Adult patients admitted to the ICU for management of severe influenza infection requiring orotracheal intubation for invasive mechanical ventilation

    phase 3 small molecule active

    1 trial

  22. APHP211003

    Pari Pharma GmbH

    Primary Bilateral Macronodular Adrenal Hyperplasia causing moderate Cushing Syndrome (Mild autonomous Cortisol secretion)

    phase 3 small molecule active

    1 trial

  23. APHP211034

    Pari Pharma GmbH

    patients hospitalized in ICU with ESBL-producing Enterobacteriaceae severe infection

    phase 3 small molecule active

    1 trial

  24. APHP211035

    Pari Pharma GmbH

    vaso-occlusive crisis due to sickle cell disease

    phase 3 small molecule active

    1 trial

  25. APHP211043

    Pari Pharma GmbH

    acute pyelonephritis (AP) in children

    phase 3 small molecule active

    1 trial

  26. APHP211044

    Pari Pharma GmbH

    urgency, limb injuries

    phase 3 small molecule active

    1 trial

  27. APHP211046

    Pari Pharma GmbH

    Any patients ≥18 years old, eligible for transfemoral TAVI with coverage for medical insurance

    phase 3 small molecule active

    1 trial

  28. APHP211053

    Pari Pharma GmbH

    Primary Sclerosing Cholangitis

    phase 3 small molecule active

    1 trial

  29. APHP211057

    Pari Pharma GmbH

    myelin oligodendrocytes glycoprotein antibody associated diseases (MOGAD)

    phase 3 small molecule active

    1 trial

  30. APHP211429

    Pari Pharma GmbH

    patients suffering from acute myocarditis confirmed on Cardiac magnetic resonance imaging.

    phase 3 small molecule active

    1 trial

  31. APHP220668

    Pari Pharma GmbH

    Major depressive disorder with current severe major depressive episode

    phase 3 small molecule active

    1 trial

  32. APHP220670

    Pari Pharma GmbH

    Pregnant women with singleton pregnancies hospitalized for threatened late miscarriage with intact membranes

    phase 3 small molecule active

    1 trial

  33. APHP220672

    Pari Pharma GmbH

    Post-aggressive immunosuppression

    phase 3 small molecule active

    1 trial

  34. APHP220674

    Pari Pharma GmbH

    respiratory distress due to upper airway obstruction in child

    phase 3 small molecule active

    1 trial

  35. APHP220676

    Pari Pharma GmbH

    Severe hyponatremia and a high risk of rapid SNa overcorrection

    phase 3 small molecule active

    1 trial

  36. APHP220763

    Pari Pharma GmbH

    Catheter related bloodstream infections due to Staphylococcus aureus

    phase 3 small molecule active

    1 trial

  37. APHP220790

    Pari Pharma GmbH

    Chondrocalcinosis

    phase 3 small molecule active

    1 trial

  38. APHP220791

    Pari Pharma GmbH

    CytoMegaloVirus infections, Kidney transplant

    phase 3 small molecule active

    1 trial

  39. APHP220797

    Pari Pharma GmbH

    Sickle cell disease

    phase 3 small molecule active

    1 trial

  40. APHP220800

    Pari Pharma GmbH

    Patients in ICU with invasive mechanical ventilation and HSV throat reactivation with 1 or no organ failures.

    phase 3 small molecule active

    1 trial

  41. APHP220805

    Pari Pharma GmbH

    incisional hernia

    phase 3 small molecule active

    1 trial

  42. APHP220814

    Pari Pharma GmbH

    Community-acquired pneumonia

    phase 3 small molecule active

    1 trial

  43. APHP220818

    Pari Pharma GmbH

    Acute mesenteric ischemia

    phase 3 small molecule active

    1 trial

  44. APHP220822

    Pari Pharma GmbH

    Subjects with PBC with a non-optimal response to UDCA.

    phase 3 small molecule active

    1 trial

  45. APHP220826

    Pari Pharma GmbH

    Adult patients discharged alive from ICU with a decreased eGFR, and/or an AKI during ICU stay and/or an elevated NT-proBNP at discharge.

    phase 3 small molecule active

    1 trial

  46. APHP220827

    Pari Pharma GmbH

    Acute Kidney Injury, Liver transplantation

    phase 3 small molecule active

    1 trial

  47. APHP220832

    Pari Pharma GmbH

    Myotonic dystrophy type 1 (DM1)

    phase 3 small molecule active

    1 trial

  48. APHP220917

    Pari Pharma GmbH

    patient with colorectal cancer with hepatic metastasis

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many Phase III pipeline programs are in the directory?

5,427 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.